Pyxis Oncology (PYXS) Cash from Operations (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Cash from Operations data on file, last reported at 10427000.0 in Q4 2025.

• On a quarterly basis, Cash from Operations rose 45.95% year-over-year to 10427000.0 in Q4 2025; TTM through Dec 2025 was 63502000.0, a 10.11% decrease from a year earlier, with the FY2025 full-year figure at 63502000.0, down 10.11% from the prior year.
• Cash from Operations for Q4 2025 stood at 10427000.0, up from 13277000.0 in the prior quarter.
• Over the last five years, Cash from Operations for PYXS reached as high as 2862000.0 in Q2 2021 and fell as low as 27679000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 15827200.0 across 5 years, with a median of 17325000.0 in 2022.
• Across the five-year window, Cash from Operations slumped 928.51% in 2022 and jumped 72.74% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 12169000.0 in 2021, then sank by 42.88% to 17387000.0 in 2022, then increased by 12.27% to 15254000.0 in 2023, then retreated by 26.46% to 19290000.0 in 2024, then surged by 45.95% to 10427000.0 in 2025.
• Per Business Quant data, the three most recent Cash from Operations figures were 10427000.0 in Q4 2025, 13277000.0 in Q3 2025, and 17263000.0 in Q2 2025.